Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00303251 · ClinicalTrials.gov registry record · Phase 1
Safety of TKI258 in Advanced/Metastatic Melanoma Subjects
A Phase 1 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 47
- Enrollment target
NCT00303251 is a Phase 1 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 47 participants.
The verdict
NCT00303251, a Phase 1 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 47 participants
- Enrollment target
Study Summary
This study is an open-label, dose-escalating study to delineate the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of TKI258. Pharmacokinetics and pharmacodynamics will be performed on all subjects. The eligible subject population consists of subjects who have been diagnosed with locally advanced or metastatic melanoma that is refractory to standard therapy or for which no curative standard therapy exists.
Interventions
- DRUG TKI258
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2006-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00303251
The ClinicalTrials.gov registry entry for NCT00303251 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 47 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which TKI258 is the first listed.
NCT00303251 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00303251 about?
NCT00303251 is a clinical study titled "Safety of TKI258 in Advanced/Metastatic Melanoma Subjects". This study is an open-label, dose-escalating study to delineate the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of TKI258. Pharmacokinetics and pharmacodynamics will be performed on all subjects. The eligible subject population consists of subjects who have been diagnosed with locally a...
What is the current status of trial NCT00303251?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 47 participants. The study started on 2006-04.
What interventions are being tested in trial NCT00303251?
The interventions under investigation include: TKI258 (DRUG).
Who is sponsoring clinical trial NCT00303251?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.